Imitrex Sc

Sumatriptan, the active ingredient in Imitrex Sc, is a Triptan (selective 5‑HT1B/1D receptor agonist) presented as a subcutaneous injection for subcutaneous use. It is indicated for the acute treatment of migraine attacks in adult patients, providing rapid relief of headache and associated symptoms.

GNH USA supplies Imitrex Sc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets and providing reliable logistics for timely delivery.

Imitrex Sc (sumatriptan) is used in the migraine pathway to treat acute headache episodes.

- Migraine: provides rapid relief of moderate to severe migraine attacks in adults. - Cluster headache: offers acute treatment of cluster headache episodes when other therapies are insufficient. - Migraine with aura: alleviates headache and associated aura symptoms during an acute attack.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Tingling or paresthesia: transient sensations of pins and needles. - Warmth or flushing: sensation of heat spreading from the injection area. - Nausea: occasional upset stomach. - Dizziness: light‑headed feeling. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Chest pain or tightness: may indicate coronary vasospasm. - Severe hypertension: abrupt increase in blood pressure. - Serotonin syndrome: agitation, hyperthermia, tremor when combined with other serotonergic agents. - Allergic reactions: rash, swelling, anaphylaxis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac arrhythmias: irregular heart rhythm.

Before using Imitrex Sc, consider the following precautions: - Cardiovascular assessment: avoid in patients with ischemic heart disease, uncontrolled hypertension, or significant arrhythmias. - Migraine subtype review: use with caution in hemiplegic or basilar migraine. - Concomitant serotonergic drugs: evaluate risk of serotonin syndrome when combined with SSRIs, SNRIs, or MAO inhibitors. - Hypersensitivity check: do not use if the patient has known allergy to sumatriptan or any excipients. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at ambient temperature: keep in the original package, protect from moisture and light.

Sumatriptan may interact with several drug classes. Review patient medication history before prescribing.

Major Interactions (Avoid): - MAO inhibitors: increased risk of serotonin syndrome. - Other triptans: additive vasoconstrictive effect. - Ergotamine derivatives: heightened vasospasm risk.

Moderate Interactions (Monitor Closely): - SSRIs/SNRIs: monitor for signs of serotonin syndrome. - Beta‑blockers: may raise sumatriptan plasma concentrations. - CYP3A4 inhibitors (e.g., ketoconazole): may increase exposure and side‑effect potential.